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Background Mycosis fungoides and Sézary syndrome (MF/SS) are rare cutaneous T-cell lymphomas. Their etiology is poorly 
understood.
Methods A pooled analysis of 324 MF/SS cases and 17 217 controls from 14 case–control studies from Europe, North 
America, and Australia, as part of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin 
Lymphoma (NHL) Subtypes Project, was carried out to investigate associations with lifestyle, medical history, family 
history, and occupational risk factors. Multivariate logistic regression models were used to calculate odds ratios (OR) 
and 95% confidence intervals (CI).
Results We found an increased risk of MF/SS associated with body mass index equal to or larger than 30 kg/m2 (OR = 1.57, 
95% CI = 1.03 to 2.40), cigarette smoking for 40 years or more (OR = 1.55, 95% CI = 1.04 to 2.31), eczema (OR = 2.38, 
95% CI = 1.73 to 3.29), family history of multiple myeloma (OR = 8.49, 95% CI = 3.31 to 21.80), and occupation as 
crop and vegetable farmers (OR = 2.37, 95% CI = 1.14 to 4.92), painters (OR = 3.71, 95% CI = 1.94 to 7.07), wood-
workers (OR = 2.20, 95% CI = 1.18 to 4.08), and general carpenters (OR = 4.07, 95% CI = 1.54 to 10.75). We also 
found a reduced risk of MF/SS associated with moderate leisure time physical activity (OR = 0.46, 95% CI = 0.22 
to 0.97).
Conclusions Our study provided the first detailed analysis of risk factors for MF/SS and further investigation is needed to 
confirm these findings in prospective data and in other populations.
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Mycosis fungoides and Sézary syndrome (MF/SS) are mature 
T-cell lymphomas that originate in the skin. The age-adjusted inci-
dence rate per 100 000 person-years in the United States in 2005–
2008 was 0.01 for SS and 0.55 for MF (1), with the latter showing a 
slight increase compared with the rate of 0.41 per 100 000 person-
years in 2001–05 (1,2). While the age-adjusted incidence rates vary 
between countries, a slightly increased incidence of MF has also 
been reported in Norway (3) and Japan (4) over the past decades. 
The incidence of MF/SS is around 1.5 times higher in males than 
females (2,3). In the United States, the highest incidence rate of 
MF is observed among African Americans, with a black-to-white 
incidence rate ratio of 1.55 (2).
MF presents in the skin with patches/plaques and is character-
ized by epidermal and dermal infiltration of small to medium-sized 
T cells with cerebriform nuclei (5). MF generally has a long natural 
history and is likely to be diagnosed at an early stage, resulting in 
a generally good prognosis with a median survival of more than 
25 years (6,7). SS is characterized by the presence of erythroderma, 
lymphadenopathy, and neoplastic T lymphocytes in the blood and 
its behavior is much more aggressive with a median survival of 
about 5 years (6,7).
Because of the rarity of these diseases, very few epidemio-
logic studies on MF/SS risk factors have been conducted thus 
far, and the only identified risk factors are male gender, advanced 
age, and African American descent (8). Smoking and alcohol 
consumption (9), several occupations and the related exposures 
(9–12), atopic diseases (9,13), sun exposure (14,15), and several 
infectious agents such as human herpesvirus 8, hepatitis C virus 
(HCV), Borrelia burgdorferi, and cytomegalovirus (16–20) have 
been studied, but their roles in the etiology of MF/SS remain 
unestablished.
To advance our understanding of MF/SS etiology, we investi-
gated associations with lifestyle, medical history, family history, and 
occupational risk factors in a pooled analysis of 324 cases and 17 217 
controls from 14 case-control studies from Europe, North America, 
and Australia as part of the International Lymphoma Epidemiology 
Consortium (InterLymph) Non-Hodgkin Lymphoma (NHL) 
Subtypes Project.
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Methods
Study Population
Detailed methodology for the InterLymph NHL Subtypes Project 
is provided elsewhere in this issue. Studies eligible for inclusion in 
this pooled analysis fulfilled the following criteria: 1) case–control 
design, with incident, histologically confirmed cases of MF/SS, and 
2) availability of individual-level data for at least several risk factors 
of interest by December 31, 2011. Most studies excluded individu-
als with a known history of solid organ transplantation or HIV/
AIDS.
Contributing studies were approved by local ethics review com-
mittees, and all participants provided written, informed consent 
before interview.
NHL Subtype Ascertainment and Harmonization
Cases were classified according to the World Health Organization 
classification (5,21) using guidelines from the InterLymph 
Pathology Working Group (22,23). Most studies had some form of 
centralized pathology review by at least one expert hematopatholo-
gist to confirm the diagnoses. Each participating study’s pathology 
review procedures, rules for NHL subtype classification, and NHL 
subtype distribution were reviewed by an interdisciplinary team of 
pathologists and epidemiologists.
Risk Factor Ascertainment and Harmonization
Each study collected data on putative NHL risk factors in a stan-
dardized, structured format by in-person or telephone interviews 
and/or self-reported questionnaires. Risk factors selected for inclu-
sion in this analysis were lifestyle, medical history, family history, 
and occupational risk factors with data from at least four studies. 
Centralized harmonization of de-identified individual-level data 
from each study was a key element of the project. Each exposure 
variable was harmonized separately, before being reviewed for con-
sistency among related exposure variables. Details of the data har-
monization rules are provided elsewhere in this issue.
Statistical Analysis
Risk of MF/SS associated with each exposure variable was exam-
ined using logistic regression models adjusted for age, race/eth-
nicity, and gender. Statistical significance of each relationship was 
evaluated by a likelihood ratio test, comparing models with and 
without the exposure variable of interest, with P values less than 
.05 identifying putatively influential factors. To evaluate effect het-
erogeneity among the 14 studies, we performed a separate logistic 
regression within each study and then quantified the variability 
of the coefficients by the H statistic, adapting the definition by 
Higgins and Thompson to categorical variables (24).
We then examined the relationship between case/control status 
and each putative risk factor considering possible effect modification 
and accounting for other potential confounders. To consider pos-
sible effect modification, we stratified the above logistic regression 
analyses by age, gender, race/ethnicity, region (ie, Northern Europe, 
Southern Europe, North America, and Australia) study, study design 
(ie population-based vs. hospital-based), or other putative risk fac-
tors identified in the analysis. Also, we set multivariate regression 
models adjusting each risk estimate for the other putative risk factor 
included one at the time, and a forward step-wise single regression 
model including all putative risk factors. Because the results did not 
change substantially with use of the multivariate models, ORs are 
presented from the minimally adjusted models only.
Because controls for most original studies were frequency-
matched to the age and gender distribution of all NHL cases, 
rather than just MF/SS, we conducted sensitivity analyses using a 
subset of controls that were frequency-matched by age and gender 
to cases of MF/SS. The results from these sensitivity analyses were 
very similar to the results obtained using the full set of controls; 
thus, we retained the full set of controls for our main analyses to 
increase statistical power.
Results
This pooled analysis included the largest number of subjects from 
North America (61% cases and 43% controls), followed by Northern 
Europe (20% cases and 34% controls), Southern Europe (17% cases 
and 19% controls), and Australia (1% cases and 4% controls). Most of 
the study population came from population-based studies (86% cases 
and 80% controls), with the remainder coming from hospital-based 
studies (14% cases and 20% controls). Of the 324 cases, 271 (84%) 
were MF, 13 (4%) were SS, and 40 (12%) were unclassified MF/
SS; the majority (78%) of MF/SS cases were histologically classified 
based on the WHO Classification. Cases and controls showed simi-
lar distributions of age, gender, and socioeconomic status (Table 1). 
MF/SS cases had higher percentages of African Americans and Asians 
compared with controls (due to the distribution in US studies).
The associations between lifestyle factors and risk of MF/
SS based on basic adjusted models are presented in Table  2. An 
increased risk was observed for people who had smoked for 40 years 
or longer (OR = 1.60, 95% CI = 1.08 to 2.38), and for obesity [body 
mass index (BMI) ≥ 30 kg/m2: OR = 1.58, 95% CI = 1.04 to 2.41] 
with reference to BMI between 18.5 and 22.4 kg/m2. However, no 
evidence of an increasing trend was observed with increasing years 
of smoking or BMI. On the other hand, compared with people 
who were not engaged in leisure-time physical activity, those who 
reported moderate (OR = 0.44, 95% CI = 0.21 to 0.91) or vigorous 
(OR = 0.50, 95% CI = 0.28 to 0.90) physical activity was inversely 
associated with a reduced risk of MF/SS. Again, no trend was 
detected with level of physical activity. We did not observe an asso-
ciation with alcohol consumption, hair dye use or sun exposure.
Among previous medical conditions, eczema was significantly 
associated with an increased risk of MF/SS (Table  3). Although 
the association was stronger for those who were diagnosed within 
10 years of MF/SS diagnosis (OR = 4.12, 95% CI = 1.54 to 11.04 
for 2–<5 years before diagnosis; OR = 4.87, 95% CI = 2.15 to 11.02 
for 5–<10 years before diagnosis), suggesting possible misdiagnosis 
of eczema as MF/SS, risk was statisticalltly elevated also for history 
of eczema beyond 10 years (OR = 1.90, 95% CI = 1.27 to 2.85). 
An evaluation of individual autoimmune diseases was not permis-
sible due to small numbers. We observed two cases of autoimmune 
diseases that activate both B and T cells, resulting in a significant 
increase in MF/SS risk. Other medical conditions, including atopic 
disorders other than eczema, psoriasis, inflammatory bowel disor-
ders, blood transfusion, HCV infection, oral contraceptive use, and 
hormone replacement therapy showed weak associations (Table 3). 
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A  family history of multiple myeloma, but not family history of 
hematologic malignancies overall, or history of other specific lym-
phohemopoietic cancer, showed an excess risk (OR  =  6.17, 95% 
CI = 2.39 to 15.91, based on six cases).
An elevated risk of MF/SS was associated with several occupations 
(Table 4), including crop and vegetable farm workers (OR = 2.76, 95% 
CI = 1.35 to 5.61), painters (OR = 3.42, 95% CI = 1.81 to 6.47), wood-
workers (OR = 2.19, 95% CI = 1.19 to 4.03), and general carpenters 
(OR = 4.50, 95% CI = 1.74 to 11.62). A significant linear trend was 
observed with years of employment for woodworkers (P for trend = 
.025) but not others (data not shown). None of the other occupations 
evaluated showed a significant association with MF/SS risk.
Results from multivariate analysis are presented in Table 5. All 
statistically significant associations remained except for vigorous 
leisure time physical activity.
Limiting our analysis to MF cases (n = 271) did not change the 
results (data not shown). No meaningful inter-study heterogeneity 
was detected.
Discussion
The results of our pooled analysis of 324 cases and 17 217 con-
trols from 14 case-control studies from Europe, North America, 
Table 1. Characteristics of studies included in the InterLymph NHL 
Subtypes Project*
Controls Cases Total
No. (%) No. (%) No. (%)
Total 17 217 (98.2) 324 (1.8) 17 541
Study
 North America
  British Columbia 845 (4.9) 42 (13.0) 887
  Mayo Clinic 1314 (7.6) 9 (2.8) 1323
  NCI-SEER 1055 (6.1) 26 (8.0) 1081
  Nebraska (newer) 533 (3.1) 7 (2.2) 540
  UCSF1 2402 (14.0) 47 (14.5) 2449
  UCSF2 457 (2.7) 54 (16.7) 511
  University of Rochester 139 (0.8) 2 (0.6) 141
  Yale 717 (4.2) 12 (3.7) 729
 Europe
  Epilymph 2460 (14.3) 38 (11.7) 2498
  Italy multi-center 1771 (10.3) 25 (7.7) 1796
  Italy (Aviano-Naples) 504 (2.9) 2 (0.6) 506
  SCALE 3187 (18.5) 41 (12.7) 3228
  United Kingdom 1139 (6.6) 15 (4.6) 1154
Australia
 New South Wales 694 (4.0) 4 (1.2) 698
Region
 North America 7462 (43.3) 199 (61.4) 7661
 Northern Europe 5820 (33.8) 65 (20.1) 5885
 Southern Europe 3241 (18.8) 56 (17.3) 3297
 Australia 694 (4.0) 4 (1.2) 698
Design
 Population-based 13 846 (80.4) 280 (86.4) 14 126
 Hospital-based 3371 (19.6) 44 (13.6) 3415
Age, y
 <30 993 (5.8) 8 (2.5) 1001
 30–39 1686 (9.8) 33 (10.2) 1719
 40–49 2543 (14.8) 57 (17.6) 2600
 50–59 3940 (22.9) 90 (27.8) 4030
 60–69 4848 (28.2) 83 (25.6) 4931
 70–79 2949 (17.1) 47 (14.5) 2996
 ≥80 258 (1.5) 6 (1.9) 264
Sex
 Male 9240 (53.7) 184 (56.8) 9424
 Female 7977 (46.3) 140 (43.2) 8117
Race
 White, non-Hispanic 15 849 (92.1) 271 (83.6) 16 120
 Black 329 (1.9) 19 (5.9) 348
 Asian 308 (1.8) 22 (6.8) 330
 Hispanic 289 (1.7) 7 (2.2) 296
 Other/unknown/missing 442 (2.6) 5 (1.5) 447
Socioeconomic status 6170 (35.8) 117 (36.1) 6287
 Medium 5292 (30.7) 94 (29.0) 5386
 High 5507 (32.0) 109 (33.6) 5616
 Other/missing 248 (1.4) 4 (1.2) 252
NHL classification
 World Health Organization 13 044 (75.8) 252 (77.8) 13 296
 Working Formulation 4173 (24.2) 72 (22.2) 4245
* NHL = non-Hodgkin Lymphoma; NCI-SEER = National Cancer Institute 
Surveillance, Epidemiology, and End Results; SCALE = Scandinavian 
Lymphoma Etiology Study; UCSF = University of California San Francisco.
Table 2. Associations between lifestyle factors and risk of Mycosis 
fungoides and Sézary syndrome*
Controls Cases
OR (95% CI)†No. (%) No. (%)
History of alcohol  
consumption
 Non-drinker 3003 (19.2) 73 (26.3) 1.00 (referent)
 Drinker (at least one  
drink per month)
8289 (52.9) 146 (52.5) 0.80 (0.58 to 1.09)
History of cigarette  
smoking‡
 No 6997 (42.7) 121 (42.9) 1.00 (referent)
 Yes 8451 (51.6) 139 (49.3) 0.97 (0.75 to 1.25)
  0–20, y 3090 (18.9) 47 (16.7) 0.86 (0.61 to 1.23)
  21–<30, y 1783 (10.9) 27 (9.6) 0.83 (0.54 to 1.28)
  30–<40, y 1737 (10.6) 24 (8.5) 0.79 (0.50 to 1.24)
  40≥, y 1742 (10.6) 40 (14.2) 1.60 (1.08 to 2.38)
  Missing 1023 (6.2) 23 (8.2)
Physical activity
 None 716 (10.1) 20 (14.7) 1.00 (referent)
 Mild 474 (6.7) 14 (10.3) 0.64 (0.29 to 1.40)
 Moderate 934 (13.2) 20 (14.7) 0.44 (0.21 to 0.91)
 Vigorous 3037 (43.0) 45 (33.1) 0.50 (0.28 to 0.90)
Usual adult BMI, kg/m2
 15–<18.5 209 (1.4) 5 (1.7) 1.30 (0.50 to 3.39)
 18.5–<22.5 2943 (19.9) 47 (15.9) 1.00 (referent)
 22.5–<25 3601 (24.4) 59 (20.0) 1.03 (0.69 to 1.52)
 25–<30 5220 (35.4) 107 (36.3) 1.25 (0.87 to 1.80)
 35–50 2175 (14.7) 55 (18.6) 1.58 (1.04 to 2.41)
Used hair dyes before 1980
 Never hair dye 1406 (14.4) 27 (13.7) 1.00 (referent)
 Ever hair dye use <1980 1101 (11.3) 21 (10.7) 1.08 (0.55 to 2.10)
 Hair dye use only 1980≥ 966 (9.9) 12 (6.1) 0.78 (0.36 to 1.71)
 Hair dye use, time period 
unknown
986 (10.1) 25 (12.7) 0.99 (0.48 to 2.05)
 Male 5071 (51.8) 108 (54.8)
Total sun exposure (h/wk)
 Q1 1508 (18.7) 24 (21.2) 1.00 (referent)
 Q2 1594 (19.8) 21 (18.6) 0.83 (0.46 to 1.50)
 Q3 1633 (20.3) 21 (18.6) 0.83 (0.45 to 1.51)
 Q4 1714 (21.3) 21 (18.6) 0.75 (0.41 to 1.40)
* CI = confidence interval; OR = odds ratio.
† OR (95% CI) adjusted for age, sex, and race.
‡ Smoked longer than 6 months or more than 100 cigarettes in lifetime.
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Table 3. Associations between medical history and risk of Mycosis fungoides and Sézary syndrome*
Controls Cases
OR (95% CI)†No. (%) No. (%)
Blood transfusion
 No 9591 (82.2) 159 (78.7) 1.00 (referent)
 Yes 1715 (14.7) 34 (16.8) 1.19 (0.81 to 1.74)
Ever used OC
 No 2164 (28.0) 32 (21.6) 1.00 (referent)
 Yes 1392 (18.0) 34 (23.0) 1.65 (0.91 to 3.01)
 Male 4044 (52.3) 80 (54.1)
Ever used HRT
 No 1716 (26.7) 37 (29.6) 1.00 (referent)
 Yes 1072 (16.7) 22 (17.6) 1.17 (0.65 to 2.13)
 Male 3351 (52.2) 64 (51.2)
Infection of HCV
 No 6746 (66.8) 128 (73.6) 1.00 (referent)
 Yes 152 (1.5) 1 (0.6) 0.47 (0.07 to 3.47)
 Missing 3194 (31.6) 45 (25.9)
Ulcer
 No 11 639 (82.8) 240 (86.3) 1.00 (referent)
 Yes 1020 (7.3) 17 (6.1) 0.93 (0.56 to 1.54)
Psoriasis
 No 10 756 (97.4) 158 (95.8) 1.00 (referent)
 Yes 256 (2.3) 7 (4.2) 1.94 (0.89 to 4.23)
Inflammatory bowel disorder
 No 14 454 (97.5) 276 (95.2) 1.00 (referent)
 Yes 179 (1.2) 7 (2.4) 1.82 (0.83 to 3.99)
Ulcerative colitis
 No 11 886 (97.2) 238 (95.2) 1.00 (referent)
 Yes 145 (1.2) 5 (2.0) 1.68 (0.67 to 4.21)
History of autoimmune disease
 No autoimmune disease 16 500 (95.8) 305 (94.1) 1.00 (referent)
 B-cell activation 127 (0.7) 2 (0.6) 1.02 (0.25 to 4.17)
 T-cell activation 577 (3.4) 15 (4.6) 1.49 (0.87 to 2.55)
 Both 13 (0.1) 2 (0.6) 9.82 (2.05 to 47.03)
Any atopic disorder‡
 No 11 285 (65.5) 185 (57.1) 1.00 (referent)
 Yes 5690 (33.0) 129 (39.8) 1.25 (0.98 to 1.61)
Allergy§
 No 9254 (68.8) 161 (61.7) 1.00 (referent)
 Yes 3338 (24.8) 73 (28.0) 0.91 (0.67 to 1.24)
Food allergy
 No 11 065 (82.2) 178 (68.2) 1.00 (referent)
 Yes 972 (7.2) 21 (8.0) 1.04 (0.64 to 1.69)
Asthma
 No 14 140 (82.8) 260 (80.7) 1.00 (referent)
 Yes 1441 (8.4) 28 (8.7) 0.99 (0.67 to 1.48)
Hay fever
 No 9198 (64.9) 132 (48.4) 1.00 (referent)
 Yes 2740 (19.3) 55 (20.1) 0.90 (0.63 to 1.30)
History of eczema
 No or <2 y before diagnosis 12 157 (84.9) 205 (74.5) 1.00 (referent)
 Yes, 2–<5 y before diagnosis 74 (0.5) 5 (1.8) 4.12 (1.54 to 11.04)
 Yes, 5–<10 y before diagnosis 92 (0.6) 7 (2.5) 4.87 (2.15 to 11.02)
 Yes, 10 y or more before diagnosis 894 (6.2) 30 (10.9) 1.90 (1.27 to 2.85)
 Yes, unknown age 343 (2.4) 10 (3.6) 2.04 (1.03 to 4.04)
 Missing 751 (5.2) 18 (6.5)
First degree family history
 Any hematologic malignancy
 No 10 152 (76.1) 202 (72.4) 1.00 (referent)
 Yes 581 (4.4) 16 (5.7) 1.16 (0.68 to 1.98)
 Multiple myeloma
 No 7671 (74.5) 162 (71.1) 1.00 (referent)
 Yes 36 (0.3) 6 (2.6) 6.17 (2.39 to 15.91)
* CI = confidence interval; HCV = hepatitis C virus; HRT = hormone replacement therapy; OC = oral contraceptives; OR = odds ratio.
† OR (95% CI) adjusted for age, sex, and race.
‡ Atopic disorders include asthma, eczema, hay fever, or other allergies, excluding drug allergies.
§ History of allergy excludes drug allergies, asthma, eczema, and hay fever.
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Table 4. Associations between occupation and risk of Mycosis 
fungoides and Sézary syndrome*
Controls Cases
OR (95% CI)†No. (%) No. (%)
Baker and miller
 No 11 152 (96.0) 209 (96.8) 1.00 (referent)
 Yes 141 (1.2) 4 (1.9) 1.80 (0.65 to 4.95)
Cleaner
 No 10 775 (92.8) 207 (95.8) 1.00 (referent)
 Yes 518 (4.5) 6 (2.8) 0.64 (0.28 to 1.46)
Driver
 No 10 467 (90.1) 200 (92.6) 1.00 (referent)
 Yes 826 (7.1) 13 (6.0) 0.83 (0.46 to 1.48)
Electrical and  
electronics worker
 No 10 589 (91.2) 202 (93.5) 1.00 (referent)
 Yes 704 (6.1) 11 (5.1) 0.83 (0.44 to 1.54)
Engine mechanic
 No 10 231 (93.9) 196 (96.1) 1.00 (referent)
 Yes 345 (3.2) 5 (2.5) 0.74 (0.30 to 1.83)
Ever worked in farming  
and farm workers  
any type
 No 9980 (85.9) 185 (85.6) 1.00 (referent)
 Yes 1313 (11.3) 28 13.0) 1.45 (0.94 to 2.22)
Crop and vegetable  
farm worker
 No 9677 (94.5) 156 (93.4) 1.00 (referent)
 Yes 226 (2.2) 9 (5.4) 2.76 (1.35 to 5.61)
Hair dresser
 No 11 144 (95.9) 210 (97.2) 1.00 (referent)
 Yes 149 (1.3) 3 (1.4) 1.24 (0.39 to 3.95)
General unspecified  
laborer
 No 10 667 (91.8) 206 (95.4) 1.00 (referent)
 Yes 626 (5.4) 7 (3.2) 0.60 (0.28 to 1.29)
Leather worker
 No 8841 (95.0) 164 (95.9) 1.00 (referent)
 Yes 147 (1.6) 4 (2.3) 1.93 (0.69 to 5.37)
Meat worker
 No 11 195 (96.4) 210 (97.2) 1.00 (referent)
 Yes 98 (0.8) 3 (1.4) 1.76 (0.55 to 5.67)
Medical worker
 No 10 423 (89.7) 198 (91.7) 1.00 (referent)
 Yes 870 (7.5) 15 (6.9) 0.89 (0.52 to 1.53)
Metal worker
 No 10 612 (91.4) 206 (95.4) 1.00 (referent)
 Yes 681 (5.9) 7 (3.2) 0.58 (0.27 to 1.24)
Painter
 No 11 099 (95.5) 202 (93.5) 1.00 (referent)
 Yes 194 (1.7) 11 (5.1) 3.42 (1.81 to 6.47)
Printer
 No 11 075 (95.3) 208 (96.3) 1.00 (referent)
 Yes 218 (1.9) 5 (2.3) 1.33 (0.54 to 3.29)
Teacher
 No 10 142 (87.3) 190 (88.0) 1.00 (referent)
 Yes 1151 (9.9) 23 (10.6) 1.12 (0.71 to 1.75)
Textile worker
 No 10 552 (90.8) 199 (92.1) 1.00 (referent)
 Yes 741(6.4) 14 (6.5) 1.30 (0.73 to 2.32)
Woodworker
 No 10 969 (94.4) 201 (93.1) 1.00 (referent)
 Yes 324 (2.8) 12 (5.6) 2.19 (1.19 to 4.03)
Table 5. Significant assocaitions from multivariate model*
Controls Cases
OR (95% CI)†No. (%) No. (%)
History of cigarette smoking‡
 No 6997 (42.7) 121 (42.9) 1.00 (reference)
 1–20, y 3090 (18.9) 47 (16.7) 0.85 (0.60 to 1.21)
 21–30, y 1783 (10.9) 27 (9.6) 0.77 (0.50 to 1.19)
 30–39, y 1737 (10.6) 24 (8.5) 0.81 (0.51 to 1.28)
 40≥, y 1742 (10.6) 40 (14.2) 1.55 (1.04 to 2.31)
Physical activity
 None 716 (10.1) 20 (14.7) 1.00 (reference)
 Mild 474 (6.7) 14 (10.3) 0.74 (0.33 to 1.64)
 Moderate 934 (13.2) 20 (14.7) 0.46 (0.22 to 0.97)
 Vigorous 3037 (43.0) 45 (33.1) 0.58 (0.32 to 1.08)
Usual adult BMI, kg/m2
 18.5–<22.5 2943 (19.9) 47 (15.9) 1.00 (reference)
 15–<18.5 209 (1.4) 5 (1.7) 1.39 (0.53 to 3.70)
 22.5–<25 3601 (24.4) 59 (20.0) 1.02 (0.69 to 1.52)
 25–<30 5220 (35.4) 107 (36.3) 1.24 (0.86 to 1.78)
 30–50 2175 (14.7) 55 (18.6) 1.57 (1.03 to 2.40)
History of autoimmune  
disease
 No autoimmune  
disease
16 500 (95.8) 305 (94.1) 1.00 (reference)
 B-cell activation 127 (0.7) 2 (0.6) 1.00 (0.24 to 4.13)
 T-cell activation 577 (3.4) 15 (4.6) 1.48 (0.86 to 2.53)
 Both 13 (0.1) 2 (0.6) 9.45 (1.80 to 49.60)
History of eczema
 No 12 100 (84.6) 202 (73.5) 1.00 (reference)
 Yes 1460 (10.2) 55 (20.0) 2.38 (1.73 to 3.29)
Family history of multiple  
myeloma
 No 7671 (74.5) 162 (71.1) 1.00 (reference)
 Yes 36 (0.3) 6 (2.6) 8.49 (3.31 to 21.80)
Crop and vegetable farm  
workers
 No 9677 (94.5) 156 (93.4) 1.00 (reference)
 Yes 226 (2.2) 9 (5.4) 2.37 (1.14 to 4.92)
Painter
 No 11 099 (95.5) 202 (93.5) 1.00 (reference)
 Yes 194 (1.7) 11 (5.1) 3.71 (1.94 to 7.07)
Woodworkers
 No 10 969 (94.4) 201 (93.1) 1.00 (reference)
 Yes 324 (2.8) 12 (5.6) 2.20 (1.18 to 4.08)
General carpenter
 No 10 493 (96.3) 196 (96.1) 1.00 (reference)
 Yes 71 (0.7) 5 (2.5) 4.07 (1.54 to 10.75)
* CI = confidence interval; OR = odds ratio.
† OR (95% CI) adjusted for age, sex, race, and all other variables listed in the table.
‡ Smoked longer than 6 months or more than 100 cigarettes in lifetime.
Controls Cases
OR (95% CI)†No. (%) No. (%)
General carpenter
 No 10 493 (96.3) 196 (96.1) 1.00 (referent)
 Yes 71 (0.7) 5 (2.5) 4.50 (1.74 to 11.62)
* CI = confidence interval; OR = odds ratio.
† OR(95% CI) adjusted for age, sex, and race.
(Table continues )
Table 4 (Continued).
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and Australia, suggest that subjects with a positive family history 
of multiple myeloma and subjects working in crop and vegetable 
farms, or as painters, carpenters or woodworkers, might be at 
an increased risk of MF/SS. A  history of eczema for more than 
10 years before MF/SS diagnosis also increased risk. Among per-
sonal and lifestyle risk factors, only obesity and prolonged cigarette 
smoking seem to convey an increased risk, while a moderate/vigor-
ous leisure time physical activity might be protective. As both MF 
and SS are rare, few results have previously been published and are 
available for comparison with our findings.
Chronic exposure to cigarette smoke has been associated with 
decreased immune responsiveness, particularly for T cells, in both 
human and animal studies (25), which would suggest a potential link 
to decreased immune surveillance and increased lymphoma risk. In 
a previous pooled InterLymph study, heavy smoking was associated 
with an increased risk of follicular lymphoma but not other NHL 
subtypes, including MF (26). In the European multicenter study of 
MF, a linear increase in MF risk with increasing pack-years of smoking 
was observed, although the trend was not statistically significant (27). 
In the analyses presented here, a significant association was observed 
among individuals who had smoked cigarettes for 40 years or more, 
but no dose–response was observed with increasing duration.
Obesity promotes a state of low-grade chronic inflammation and 
increased production of proinflammatory cytokines such as inter-
leukin (IL)-6, tumor necrosis factor-α, IL-1b, and leptin (28). These 
cytokines can deregulate T- and B-cell responses and enhance B-cell 
proliferation and survival, factors that may provide a milieu that favors 
lymphomagenesis (29). In our analysis, a BMI greater than or equal to 
30 kg/m2 was associated with an increased risk of MF/SS, although we 
were unable to support with statistical significance the observed lin-
ear increase in risk by increasing BMI. A similar finding was reported 
for diffuse large B-cell lymphoma in a previous InterLymph study of 
NHL overall and common NHL subtypes; however, MF/SS was not 
analyzed as a separate outcome in that study (30).
Moderate physical activity may improve immune function and it 
may therefore protect against NHL and possibly MF/SS (31). In our 
study we found that, compared with people who were not engaged in 
leisure-time physical activity, those who engaged in moderate and vig-
orous physical activity experienced a reduced risk of MF/SS. However, 
the decrease in MF/SS risk by increasing level of physical activity was 
not linear, and the multivariate analysis partially weakened the inverse 
association. Previous reports suggest that moderate exercise may 
reduce NHL risk (32,33). More research in this area is warranted.
In agreement with a previous InterLymph study (13), we found 
that a previous medical history of eczema was associated with an 
increased risk of MF/SS, which appeared to be stronger for those 
who were diagnosed within 10 years of MF/SS diagnosis. Such a 
pattern might suggest the possibility that early MF may be mis-
taken for eczema in some cases. Alternatively, the association with 
eczema may be an indicator of eczema as an early disease rather 
than a risk factor as it often goes undiagnosed for years. However, 
the risk remained significantly elevated for those who were diag-
nosed more than 10  years before MF/SS diagnosis. Eczema is a 
form of chronic dermatitis which is known to have a pathogenetic 
association with early stages of MF (34). Specific autoimmune dis-
eases were rare and no analysis of their associations with MF/SS risk 
was feasible; after categorizing autoimmune diseases by whether B 
or T cells were activated, no association was observed. However, 
two cases of autoimmune diseases that activate both B and T cells 
were observed, resulting in an elevated MF/SS risk. B cell activating 
diseases included Hashimoto thyroiditis, hemolytic anemia, myas-
thenia gravis, pernicious anemia, rheumatoid arthritis, Sjögren’s 
syndrome, and systemic lupus erythematosus. T cell activating dis-
eases included celiac disease, immune thrombocytopenic purpura, 
inflammatory bowel disorder (Crohn’s disease, ulcerative colitis), 
multiple sclerosis, polymyositis or dermatomyositis, psoriasis, sar-
coidosis, systemic sclerosis or scleroderma, and type 1 diabetes.
A role for genetic susceptibility in MF/SS is supported by the 
accumulating evidence of common genetic variations altering MF 
risk (35,36). In our study, persons with a family history of multiple 
myeloma had an excess risk of MF/SS, but no association was found 
with family history of any hematologic malignancy. In a previous 
pooled InterLymph analysis, risk of specific NHL subtypes, includ-
ing T-cell lymphomas (MF/SS were not separately evaluated), were 
elevated among subjects who reported a family history of hema-
tologic malignancies in first-degree relatives, particularly multiple 
myeloma in males (37). However, it is also possible that since mul-
tiple myeloma and MF are increased in blacks (37), this may con-
found the association.
The evaluation of occupational risk factors showed that crop 
and vegetable farm workers, painters, woodworkers and carpen-
ters experienced an increased risk of MF/SS. Although we did not 
examine specific occupational exposures, our findings are con-
sistent with the results of other studies that examined exposures 
potentially encountered in these occupations. In a European case–
control study, occupational exposures to the broad category of aro-
matic and/or halogenated hydrocarbons, which are widely used as 
solvents, and to pesticides in general were identified as potential 
risk factors for MF (10). An excess risk of NHL among farmers 
and agricultural workers has been repeatedly reported, suggesting a 
potential link with farming exposures including pesticides (38,39). 
Among the most commonly used agrochemicals, organophosphate 
insecticides were associated with an increased risk in the European 
Epilymph study, limited to the chronic lymphocytic leukemia sub-
type (40). Other occupations previously associated with an increase 
in MF risk include different manufacturing industries, such as pet-
rochemical, textile, and various metal industries (41–43). Painters 
and woodworkers may also be exposed to solvents in paint thinners 
and paint and grease removers, including benzene and trichloro-
ethylene previously associated with increased risk of other NHL 
subtypes in prior reports from included studies (44,45). Other 
exposures possibly related to the excess risk we observed for these 
occupations include chlorophenols, wood dust, and molds (Cocco 
P, unpublished data). Our results suggest that these and other 
potentially harmful exposures should be explored in greater detail 
in future investigations using advanced occupational exposure 
assessment methods.
Although this is the largest study to date that examines numer-
ous putative risk factors in relation to MF/SS, the small number 
of subjects was still a limitation. All cases were histologically con-
firmed, but centralized review of all cases by a team of study pathol-
ogists was not feasible, and thus some misclassification may be 
present. As multiple hypotheses have been tested and a number of 
comparisons have been made, chance findings cannot be ruled out. 
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Since only 13 SS cases were included in this study, we were unable 
to examine associations specific to SS; therefore, the observed asso-
ciations were predominantly driven by MF and may not apply to 
SS. Another limitation is related to the number of comparisons we 
made, which might have generated several positive findings as the 
sole result of chance. However, negative findings might have been 
missed as the study size is insufficient to detect weaker associations. 
In conclusion, our pooled analysis of lifestyle factors, medical his-
tory, and occupation and MF/SS suggests potential positive asso-
ciations with elevated BMI, long-term cigarette smoking, eczema, 
and family history of multiple myeloma, and a potential negative 
association with moderate leisure time physical activity. Our find-
ings for farming and other occupations point to avenues for addi-
tional research to identify specific occupational exposures that may 
be responsible for these associations. Future research is warranted 
to confirm these findings in prospectively collected data and in 
other populations.
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